

FORM PTO-1449		U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
				U 012951-1	09/768,442
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT	
(Use several sheets if necessary)				Chun-Ying HUANG, et al.	
				FILING DATE	GROUP
				January 24, 2001	1614

O I P E
JAN 29 2002
U. S. PATENT & TRADEMARK OFFICE

REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<i>Ch</i>	AA	6	1	4	0	3	4	6	10/2000 Andrulis, Jr. et al.
	AB								
	AC								
	AD								
	AE								
	AF								

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
<i>Ch</i>	AG	9 9 6 1 0 8 5	12/1999	WO			X	
<i>Ch</i>	AH	9 4 2 0 0 8 5	9/1994	WO			X	
	AI							
	AJ							
	AK							

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

<i>Ch</i>	AL	Kong, H.L., et al. "Phase II trial of thalidomide in unresectable hepatocellular carcinoma - a cancer Therapeutics Research...Study" Abstract only, Database Accession Number 2001:15190 (May 2001)
<i>Ch</i>	AM	Aguayo, A., et al. "Liver Cancer" <i>Clinics in Liver Disease</i> , Vol. 5, No. 2, p. 479-507, (2001)
<i>Ch</i>	AN	Patt, Y.Z., et al. "Durable Clinical Response of Refractory Hepatocellular Carcinomas to Orally Administered Thalidomide" <i>Am. J. Clin. Oncol.</i> , Vol. 23, No. 3, p. 319-321, (2000)
<i>Ch</i>	AO	Patt, Y.Z., et al. "Phase II Trail of Thalomid (Thalidomide) for Treatment of Non-Resectable Hepatocellular Carcinoma (HCC)" Abstract only, (May 2000)
<i>Ch</i>	AP	Politi, P.M. "Ensayos Clinicos en Cancer" <i>Medicina (Buenos Aires)</i> , Vol. 60, Supl. II, p. 61-65, (2000)
<i>Ch</i>	AR	Konno, H., et al. "Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies" <i>J. Hepatobiliary Pancreatic Surgery</i> , Vol. 6, p. 1-6, (1999)

EXAMINER <i>Ch</i>	DATE CONSIDERED <i>4/10/02</i>
--------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED